Overexpression of fibroblast growth factor receptor 3 (FGFR3) has been shown to drive oncogenesis in a subset of patients with multiple myeloma. However, epithelial cancers — such as bladder ...

Tyra Biosciences' TYRA-300, an oral FGFR3 inhibitor, showed promising efficacy but raised concerns with some FGFR1/2-driven adverse events, causing a significant stock drop. TYRA-300 demonstrated ...

Achondroplasia risk factors Achondroplasia is caused by a spontaneous mutation in a specific gene called FGFR3. About 98% of cases result from the exact same change in the DNA in this gene.

11 xenograft mouse model, accompanied with inhibition of phospho-FGFR3, phospho-JAK2, phospho-STAT3 and Cyclin D2 levels. In sum, AZD1480 blocks proliferation, survival, FGFR3 and JAK/STAT3 ...

FGFR3 mutations and HER2 positivity in bladder cancer guide treatment with erdafitinib and fam-trastuzumab deruxtecan-nxki, respectively. Emerging biomarkers such as KIM-1 in renal cell carcinoma and ...

Tasurgratinib (also known as E-7090) is an oral selective FGFR1, FGFR2, and FGFR3 inhibitor that, if approved, will join other drugs in the class on the market, including Incyte’s Pemazyre ...